Drug Utilization Review Board
Minutes Draft

Name of Meeting: Drug Utilization Review Board
Date of Meeting: February 9, 2017
Length of Meeting: 2 hour and 20 minutes
Location of Meeting: DMAS Board Room 13th Floor

Members Present:
Randy Ferrance, MD, Chair
Bill Rock, PharmD, Vice Chair
Jonathan Evans, MD
Sandra Dawson, RPh
Seth Brant, MD
Denese Gomes, NP
Wendy Nash, PharmD
Kathryn Reid, PhD

Members Not Present:
Michele Thomas, PharmD
Avtar Dhillon, MD

DMAS Attendees:
Donna Proffitt, RPh, Pharmacy Program Manager
Rachel Cain, PharmD
Keith Hayashi, RPh

Contractors:
MaryAnn McNeil, RPh, Clinical Pharmacy Manager, Conduent
Jenness Vaccarella, Conduent
Tina Carter, CPhT, Conduent

Vendors:
Debbie Moody, RPh, Magellan Health Services
Nancy Eldin, PharmD, Magellan Health Services

Visitors:
Patti Rohman, Otsuka
Jon Yochum, AMAG
Ken Jennings, BMS
Jay Harding, ViiV
Cherie Robertson, Pfizer
Steve Patterson, Alkermes
Rick Kegler, Otsuka
Brad Leiser, Mylan
Sandy Kapur, Conduent
Mark Stephens, Pfizer
Anson Williams, Conduent
Robert Wright, Indivior
Matt Sheffield, Thera
David Large, Supernus
Bryan Merrell, Bayer

Call to Order and Introductions

Dr. Ferrance called the meeting to order at 2:05pm.

Minutes – November 10, 2016

Meeting minutes were reviewed and approved.

By-Laws

Dr. Cain presented revised By-Laws, voting will take place at the next DUR Board meeting scheduled for May 11, 2017.

NEW Drugs

Rayaldee® (calcifediol) – Ms. McNeil presented the drug information. The Board requested utilization (1st Quarter) for the next DUR Board meeting, May 11, 2017. No action required by the Board.

Rubraca™ (rucaparib) –Ms. McNeil presented the drug information and service authorization criteria recommendations for Rubraca. The motion was made to accept the criteria as written with the recommendation of quantity limitations added to the SA form. The Board seconded and approved the criteria.

Vemlidy® (tenofovir alafenamide) –Ms. McNeil presented the drug information. No action required by the Board.

New Drugs: PDL Eligible; Physician-administered – Ms. McNeil presented the drug information for new Physician-administered drugs and PDL Eligible drugs. With regard to the Physician Administered Drugs, the Medical Support unit and the Pharmacy unit will be working together on reviews of these medications. There was discussion around Spinraza™(nusinersen), the first and only US Food and Drug Administration (FDA)-approved treatment indicated for spinal muscular atrophy (SMA) in pediatric and adult patients. In addition, the cost for one year of treatment is $750,000. No action required by the Board.

Topics for Discussion

Analysis of Compounded Prescriptions – Ms. McNeil presented the data findings as requested by the DUR Board from the November meeting. The Point of Sale (POS) system changes have been approved for implementation as an emergency work order (EWO) for April 2017. The Board requested this topic tabled for next DUR Board meeting, after review of impact from the EWO implementation.

Pediatric Narcotic Utilization –Ms. McNeil presented the pediatric narcotic utilization reports from October 2016 thru December 2016 based on Fee for Service (FFS) data only; Managed Care data not provided. The board questioned the ability for DMAS to obtain the Managed Care data for more accurate reporting. No specific timeframe was provided. The Board requested continuance of pediatric narcotic utilization reports.

Morphine Equivalent Dosing for Narcotics – Ms. McNeil presented the opioid review which includes three components: standard fourth quarter reports, comparison of 2nd, 3rd and 4th quarter utilization and a heat map at the request of the DUR Board from the previous meeting. The board questioned the rates of prescribing / Rx's per unit of population for heat map reporting. The data reflected in the heat map is Fee for Service (FFS) only and does not include Managed Care to date. The Board requested this topic tabled for the next DUR Board meeting, May 11, 2017 with ***no*** heat map.

HIV / AIDS Medication Utilization – Ms. McNeil began by presenting as a protected drug class by the P & T Committee. Discussions ensued and several questions were raised about patient utilization/adherence; what drugs are non-specialists prescribing, and are these drugs providing effective patient care? The board requested Ms. Gomes, NP, review and provide the DUR Board with any suggestions/recommendations in managing this class of medications that may benefit the Medicaid recipients. Review at the next DUR Board meeting, May 11, 2017.

Synagis Update – Review tabled for the next DUR Board meeting, May 11, 2017.

DUR Quarterly Newsletter – Review tabled for the next DUR Board meeting, May 11, 2017.

Reports

ProDUR and RetroDUR- Review tabled for the next DUR Board meeting, May 11, 2017.

Utilization Analysis Reports- Review tabled for the next DUR Board meeting, May 11, 2017.

Top Diagnoses by Age- Review tabled for the next DUR Board meeting, May 11, 2017.

AAP Report- Ms. McNeil reviewed the reports provided in the DUR Board binder which included a trending report as requested by the DUR Board at the previous meeting.

Meeting was adjourned at 4:25 pm.

Next DUR Board meeting scheduled for May 11, 2017.